Microvessel density for melanoma prognosis

Histopathology

Volumn 47, Issue 2, 2005, Pages 186-194

  Depasquale, I ^a   Thompson, W Douglas ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Angiogenesis; Breslow thickness; Chalkley count; Melanoma; Prognosis

Indexed keywords

CD31 ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ANTIBODY LABELING; ARTICLE; CANCER RECURRENCE; CANCER RISK; CELL DENSITY; CHALKLEY TECHNIQUE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METHODOLOGY; MICROVASCULATURE; MICROVESSEL DENSITY; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SCORING SYSTEM; TECHNIQUE; TUMOR VOLUME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REGRESSION ANALYSIS;

EID: 23444434188     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02193.x     Document Type: Article

References (38)

1. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst. 1972; 48; 347-356.
2. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am. J. Pathol. 1988; 133; 419-423.
3. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001; 19; 3635-3648. [Review]
4. Srivastava A, Hughes LE, Woodcock JP, Shedden EJ. The significance of blood flow in cutaneous malignant melanoma demonstrated by Doppler flowmetry. Eur. J. Surg. Oncol. 1986; 12; 13-18.
5. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab. Invest. 1992; 67; 331-337.
6. Fallowfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J. Pathol. 1991; 164; 241-244.
7. Smolle J, Soyer HP, Hofmann-Wellenhof R, Smolle-Juettner FM, Kerl H. Vascular architecture of melanocytic skin tumors. A quantitative immunohistochemical study using automated image analysis. Pathol. Res. Pract. 1989; 185; 740-745.
8. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, De Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 1997; 7 (Suppl. 26).
9. Marcoval J, Moreno A, Graells J et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J. Cutan. Pathol. 1997; 24; 212-218.
10. Straume O, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int. J. Oncol. 1999; 15; 595-599.
11. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am. J. Pathol. 2001; 159; 223-235.
12. Rongioletti F, Miracco C, Gambini C, Pastorino A, Tosi P, Rebora A. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay. Am. J. Dermatopathol. 1996; 18; 474-477.
13. Massi D, Franchi A, Borgognoni L, Paglierani M, Reali UM, Santucci M. Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic analysis. Virchows Arch. 2002; 440; 22-28.
14. Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma. Ann. Surg. Oncol. 1999; 6; 70-74.
15. Dome B, Paku S, Somlai B, Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J. Pathol. 2002; 197; 355-362.
16. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR III. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J. Clin. Oncol. 2002; 20; 1826-1831.
17. Carnochan P, Briggs JC, Westbury G, Davies AJ. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br. J. Cancer 1991; 64; 102-107.
18. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am. J. Pathol. 1994; 145; 510-514.
19. Busam KJ, Berwick M, Blessing K et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol. 1995; 147; 1049-1056.
20. Ilmonen S, Kariniemi AL, Vlaykova T, Muhonen T, Pyrhonen S, Asko-Seljavaara S. Prognostic value of tumour vascularity in primary melanoma. Melanoma Res. 1999; 9; 273-278.
21. Chalkley H. Method for the quantitative morphological analysis of tissues. J. Natl Cancer Inst. 1943; 4; 47-53.
22. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol. 1995; 177; 275-283.
23. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast. Reconstr. Surg. 1993; 91; 94-98.
24. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994; 80; 188-197.
25. Dicker TJ, Kavanagh GM, Herd RM et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br. J. Dermatol 1999; 140; 249-254.
26. Balch CM, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Intergroup Melanoma Surgical Trial. Ann. Surg. Oncol. 2000; 7; 87-97 [comment].
27. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 1996; 32A; 2474-2484 [Review].
28. Sawa Y, Yoshida S, Ashikaga Y, Kim T, Yamaoka Y, Shiroto H. Lymphatic endothelium expresses PECAM-1. Tissue Cell 1998; 30; 377-382.
29. Thompson WD. Tumour versus patient: vascular and tumour survival versus prognosis. J. Pathol. 2001; 193; 425-426.
30. Giatromanolaki A, Koukourakis MI, Sivridis E, O'Byrne K, Gatter KC, Harris AL. 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J. Pathol 2000; 192; 140-149.
31. Srivastava A, Laidler P, Hughes LE, Woodcock J, Shedden EJ. Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. Eur. J. Cancer Clin. Oncol. 1986; 22; 1205-1209.
32. Srivastava A, Hughes LE, Woodcock JP, Laidler P. Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour. Br. J. Cancer 1989; 59; 89-91.
33. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br. J. Cancer 2000; 82; 339-347.
34. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324; 1-8.
35. Jackson DG, Prevo R., Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001; 22; 317-21 [Review].
36. Shields JD, Borsetti M, Rigby H et al. Lymphatic density and metastatic spread in human malignant melanoma. Br. J. Cancer 2004; 90; 693-700.
37. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004; 9 (Suppl. 1); 11-18.
38. Imatinib mesylate and bevacizumab in treating patients with advanced melanoma or other advanced cancers. Bevacizumab with or without interferon alfa in treating patients with metastatic malignant melanoma, http://www. clinicaltrials.gov/